| Cas No.: | 942123-43-5 |
| Chemical Name: | SB9200,SB 9200,SB-9200 |
| Synonyms: | SB9200,SB 9200,SB-9200 |
| SMILES: | N1=C(N)C2N=CN([C@H]3O[C@@H](COP(O[C@@H]4[C@@H](CO)O[C@H](N5C(=O)NC(=O)C=C5)[C@H]4OC)(SCOC(OC(C)C)=O)=O)[C@H](O)C3)C=2N=C1 |
| Formula: | C25H34N7O13PS |
| M.Wt: | 703.62 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. |
| In Vitro: | Inarigivir soproxil (SB 9200) is an oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV). Inarigivir soproxil is shown to inhibit HCV replication and the range of inhibition is comparable between genotypes 1a and 1b. Inarigivir soproxil demonstrates pan-genotypic antiviral activity against HCV. Inarigivir soproxil is active against DAA-resistant HCV variants[1]. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|